Vanguard Asset Management’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
LCM
Vanguard Asset Management's STOK Position: Q3 2026 in Review
Vanguard Asset Management increased its Stoke Therapeutics (STOK) stake by 19% in Q3 2026, buying an estimated $144K and bringing the position to 29,896 shares worth $777K. The position accounts for ﹤0.01% of the portfolio, ranked #1981.
Vanguard Asset Management first reported a position in STOK in Q1 2026 and has held it in 3 quarters since. The position peaked at $822K in Q2 2026. 185 funds tracked by Wall St. Rank hold STOK as of Q3 2026.
- Vanguard Asset Management held 29,896 shares of Stoke Therapeutics worth $777K as of Q3 2026.
- Vanguard Asset Management bought 4,782 Stoke Therapeutics shares in Q3 2026, an estimated $144K.
- Stoke Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1981 holding.
- Vanguard Asset Management first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's Stoke Therapeutics position peaked at $822K in Q2 2026.
- 185 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.